ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer-Reference-Cited by-同舟云学术

ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer

Published:2022-06-29 Issue:3 Volume:21 Page:135-142
ISSN:2312-3168
Container-title:Siberian journal of oncology
language:
Short-container-title:Sib. onkol. ž.

Author:

Tarakanova V. O.¹^ORCID,Krakhmal N. V.¹^ORCID,Patalyak S. V.¹^ORCID,Tarasov M. N.²^ORCID,Babyshkina N. N.¹^ORCID,Vtorushin S. V.¹^ORCID

Affiliation:

1. Cancer Research Institute, Тomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of the Ministry of Health of Russia

2. Siberian State Medical University of the Ministry of Health of Russia

Abstract

The purpose of the study was to generalize information regarding the molecular and biological mechanisms involved in the resistance to endocrine therapy with aromatase inhibitors in patients with luminal breast cancer. Material and Methods. The literature search was conducted using Medline, Cochrane Library, Elibrary and PubMed databases. Results. The review highlights the results of international studies on molecular and biological characteristics of breast tumors and their relationship with the effectiveness of hormone therapy. Particular attention was paid to the description of modern studies on ROR1 and BMI-1 proteins and their contribution to the development of tumor resistance to treatment. Conclusion. The analysis of the world literature confrms the relevance of studying the molecular and genetic characteristics of tumor tissue in patients with luminal breast cancer. The data obtained were compared to the clinical course and response to hormone therapy in order to standardize them for implementation in everyday practice as the “gold standard of diagnosis”.

Publisher

Tomsk Cancer Research Institute

Subject

Cancer Research,Oncology

Reference38 articles.

1. Siegel R.L., Jakubowski C.D., Fedewa S.A., Davis A., Azad N.S. Colorectal cancer in the young: epidemiology, prevention, management. Am Soc Clin Oncol Educ Book. 2020; 40: 1–14. doi: 10.1200/ EDBK_279901.

2. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19): 10869–74. doi: 10.1073/pnas.191367098.

3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001): 1341–52. doi: 10.1016/S0140-6736(15)61074-1.

4. Araki K., Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018; 25(4): 392–401. doi: 10.1007/s12282-017-0812-x.

5. Zhao H., Zhou L., Shangguan A.J., Bulun S.E. Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol. 2016; 57(1): 19–33. doi: 10.1530/JME-15-0310.